NAUTILUS BIOTECHNOLOGY INC

NAUTNASDAQ

🏆 #3828 by market capEarnings Oct 26US Equity

$1.36▲ $0.29 (+21.43%)

Market closed · at close

🔔

Track NAUT

Get earnings, price moves & breaking news on Telegram

Track

24h▲ 21.4%

7d▲ 41.6%

14d▲ 39.9%

30d▲ 40.1%

ytd▼ 30.3%

1y▲ 65.9%

🏦Market Cap

$173M

Small Cap

📈Revenue Growth (YoY)

+0.0%

Slowing

📊Gross Margin

-919.5%

Thin

💵FCF Margin

-27295.3%

Thin

⚖️P/S Ratio

877.4x

Expensive

Otter Score

Weak

Trading Snapshot

Day Range: $1.34 – $1.38
52-Week Range: $0.80 – $4.31
Volume: $4.32B
Avg Volume: $5.20B
Shares Outstanding: 127.3M
Next Earnings: Oct 24, 2026

Fundamentals Snapshot

Annual Revenue: $190,000
Last Q Revenue: $190,000
P/E Ratio: -2.9
P/S Ratio: 877.4x
EPS (TTM): $-0.45
Dividend Yield: 0.00%
Dilution (1yr): +0.4%

Why Investors Own NAUT

✓High-growth profile — revenue up +10.1% YoY with expanding US Equity exposure.
✓Healthy economics — 41% gross margin and 10% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

NAUTILUS BIOTECHNOLOGY INC

NAUT

Financial Trends

Revenue

$0▲ +0.0% YoY

Operating Income

−$67M▼ −18.0% YoY

Free Cash Flow

−$52M▼ −15.2% YoY

Shares Outstanding

126.3M▲ +0.4% YoY

Net Cash

−$18M▼ −$15M YoY

StockOtter · stockotter.space

About NAUTILUS BIOTECHNOLOGY INC

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to process labeled multi-affinity reagent binding and imaging cycles rapidly to decode and quantify the proteins present in biological samples. In addition, the company offers single-molecule library preparation kits, flow cells, affinity reagents, and instrument run buffers to perform multi-cycle analysis runs. It has a research collaboration agreement Genentech, Buck Institute, Allen Institute, Cornell University and the Qatar Foundation, and Michael J. Fox Foundation. Nautilus Biotechnology, Inc. was founded in 2016 and is headquartered in Seattle, Washington.

🦦